Drug Profile
Research programme: epothilone cancer therapeutics - Calando Pharmaceuticals/R&D-Biopharmaceuticals
Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator R&D-Biopharmaceuticals
- Class
- Mechanism of Action Mitosis inhibitors; Tubulin polymerisation promoters
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for research development in Cancer in USA
- 24 Apr 2008 Insert Therapeutics has been acquired and merged into Calando Pharmaceuticals
- 02 Mar 2007 Early research in Cancer in USA (unspecified route)